The pancreas is a major source of ghrelin in the perinatal period, whereas gastric production progressively increases after birth. Loss of function of the genes for ghrelin or for the constitutively activated growth hormone secretagogue receptor (GHSR) does not affect birth weight and early postnatal growth. However, ghrl À/À or ghsr À/À mice fed a high fat diet starting soon after weaning are resistant to diet-induced obesity, suggesting that ghrelin affects the maturation of the metabolic axes involved in energy balance. In addition, animal and human studies suggest that GHSR plays a physiological role in linear growth. In mice, absence of the GHSR gene is associated with lower insulin-like growth factor 1 concentrations and lower body mass in adult animals, independently of food intake. In humans, a mutation of the GHSR gene that impairs the constitutive activity of the receptor was found in two families with short stature. Administration of acylated ghrelin to rat pups directly does not affect weight gain. In contrast, administration of ghrelin to pregnant or lactating rats results in greater fetal weight and postnatal weight gain, respectively, suggesting that maternal ghrelin may stimulate perinatal growth. These data point toward a physiological role for ghrelin and GHSR in growth and/or in the maturation of hormonal systems involved in the regulation of energy balance.
Introduction
Ghrelin is a 28-amino-acid peptide resulting from the enzymatic processing of proghrelin by prohormone convertase 1/3.
1 It is secreted primarily by the fundus of the stomach in adult humans 2 and rodents. 3 Ghrelin circulates as both desacyl and acylated forms. This n-octanoyl acylation on one of its serine residues (Ser 3 ) is unique to ghrelin and is necessary for the binding of ghrelin to the growth hormone secretagogue receptor (GHSR) 4 (reviewed in van der Lely et al.
5
). In adult humans and rodents, exogenous administration of ghrelin stimulates growth hormone (GH) secretion and has potent orexigenic effects. Both effects are mediated by the GHSR, a constitutively activated receptor that signals with 50% activity even in the absence of ghrelin. 6 In addition, ghrelin promotes a positive energy balance through the stimulation of adipogenesis via GHSR-independent pathways. 7 This effect is independent of food intake.
However, the physiological role of endogenous ghrelin still remains a matter of debate. The aim of this article is to review the data pertaining to the physiology and potential role of ghrelin during growth and development in humans and rodents.
Ontogeny of ghrelin
Both acylated and desacyl ghrelin are present in fetal-rat plasma by day 20 of gestation. 8 Acylated ghrelin concentrations are low in the fetus and increase markedly shortly after birth. 9 Interestingly, tissue distribution of ghrelin differs greatly in the fetal and postnatal periods. By day 18 of gestation, ghrelin is present at low levels in the fetal stomach, 8, 10 a tissue traditionally regarded as a major source of circulating ghrelin in the adult. Stomach ghrelin concentrations increase after birth and reach adult levels by 3-5 weeks. 9 We have shown by immunohistochemistry that preproghrelin-positive cells are already abundant in rat stomach in the perinatal period, but that only a few cells are also positive for ghrelin, suggesting that, at least in this species, the low levels of ghrelin in the fetal and neonatal stomach are attributed to the low level of preproghrelin processing, rather than to the low preproghrelin gene expression. 11 In contrast to the stomach, immunoreactive ghrelin is abundant in the fetal rat pancreas. Ghrelin gene expression is 6-7 times higher in the fetal pancreas than in the fetal stomach on day 20 of gestation, 8 and decreases progressively after birth until weaning, to become virtually undetectable in the adult animal. 9 Another difference with the stomach is that immunohistochemistry detects only a few preproghrelin-positive cells in the rat pancreatic islets. Each of these cells also stains for ghrelin, suggesting that preproghrelin is processed in all cells where it is present. In the pancreas, ghrelin is produced mainly in the islets of Langerhans. Ghrelin is present either in glucagon-producing a-cells or in an independent cell type (e-cell). Whether these e-cells truly form a novel, distinct endocrine cell type remains to be clarified. 12 Similar to all other endocrine cell types in the pancreas islet, specification of ghrelin-producing cells requires Ngn-3, a transcription factor necessary for the differentiation of the endocrine precursor into mature cells. However, in the absence of Nkx2.2, a transcription factor required for the specification and maintenance of insulinproducing b-cells, and, to a lesser extent, of glucagonproducing a-cells, a marked increase in the number of ghrelin cells is observed, suggesting that the specification of these three cell types is closely linked. 13 In humans, immunoreactive ghrelin is present in umbilical cord blood samples as early as by the twentieth week of gestation in concentrations that are of the same magnitude as those reported in adults. Ghrelin levels are higher in small-for-gestational-age neonates compared with appropriatefor-gestational-age neonates.
14 Postmortem studies have also
shown that ghrelin-immunoreactive cells are abundant in the fetal and neonatal pancreas, representing up to 11% of all islet cells at birth. 15 The role of pancreas ghrelin in perinatal glucose homeostasis remains to be investigated.
Ghrelin, GH, GHSR and linear growth
The GH response to exogenous administration of ghrelin is present in the rat by the end of the first postnatal week. 10 Whether endogenous ghrelin plays a role in GH physiology in the perinatal period however remains, unclear. Deletion of the ghrelin gene does not affect litter size, birth weight and postnatal growth in mice despite a complete absence of tissue and plasma ghrelin. Random concentrations of GH 16 and insulin-like growth factor 1 17 (measured in adult animals) are similar in ghrl À/À and ghrl þ / þ animals.
In humans, GH concentrations are typically elevated during the first postnatal week in newborns, and play an important physiological role in the prevention of neonatal hypoglycemia. However, the absence of a positive correlation between umbilical cord ghrelin and GH concentrations does not support the hypothesis that ghrelin is a main driver of neonatal GH secretion. 18 To our knowledge, there has been no report of impaired GH secretion or linear growth associated with abnormal ghrelin secretion in humans.
In contrast, there is recent evidence pointing toward a physiological role of GHSR in both rodents and humans. In mice, loss of function of the GHSR gene is associated with lower insulin-like growth factor 1 concentrations and a lower body mass in adult animals that is independent of food intake and energy expenditure. 4 In humans, Pantel et al. 19 found a mutation of the GHSR gene in two families in which short stature was inherited in a dominant manner. In keeping with a dominant inheritance with variable penetrance, short stature was present in the proband, who was homozygous for the mutation, and in some of the family members who were heterozygous for the mutation. This missense mutation markedly decreased the constitutional activity of the receptor but preserved its ability to respond to ghrelin, again suggesting that GHSR is required for optimal linear growth. These data suggest that the constitutive activity of GHSR is important for the integrity of the GH-insulin-like growth factor 1 axis, whereas ghrelin itself plays little role in normal linear growth.
Ghrelin, food intake and energy balance
Exogenous administration of acylated ghrelin increases food intake in adult humans and rodents, whereas plasma concentrations of endogenous ghrelin increase with fasting and decrease following energy intake. These data originally suggested that ghrelin could serve as an endogenous orexigenic signal and modulate energy balance. 20 However, ghrelin concentrations are inversely related to body mass index in adult humans 21 and rodents, suggesting that ghrelin appropriately senses body stores but does not play a pathophysological role in the development of either obesity or anorexia nervosa. Does ghrelin affect perinatal energy balance? Exogenous administration of ghrelin directly to pups before weaning does not affect weight gain. 10 These data likely reflect the immaturity of the brain and of the signaling pathways linking ghrelin and neuropeptide-Y to downstream targets regulating food intake. 22, 23 In addition, in lactating pups, nutrient availability is more tightly controlled than in adult animals that have free access to food, and ghrelin administration in suckling pups may therefore not translate into a detectable increase in milk consumption. As mentioned above, loss of function of the ghrelin and GHSR genes does not affect litter size, birth weight, food intake or preweaning growth rate, and, in our mind, the lower body mass observed in adult ghsr À/À animals most likely reflects an impaired GH-insulin-like growth factor 1 axis. However, when ghrl À/À17 or ghsr À/À24 animals are fed a high-fat diet starting shortly after weaning (4-6 weeks), their weight gain is slower compared with wild-type animals. This resistance to the obesogenic effects of a high-fat diet that develops in animals deficient in ghrelin or in its receptor shows that early nutritional intervention may permanently impair the central pathways involved in energy balance, suggesting a role for ghrelin and GHSR in the maturation of these pathways. In humans, the role of ghrelin or GHSR in postnatal growth remains unclear. James et al. 25 found a modest association between lower cord blood ghrelin concentrations and slower weight gain for the first 12 postnatal weeks, whereas Iniguez et al. 26 reported a greater decrease in plasma ghrelin concentrations following i.v. glucose load in smallfor-gestational-age infants experiencing a slower weight gain during the first year. Later, the inverse correlation between body mass index and ghrelin concentrations, as well as the physiological postprandial decrease in acylated and desacyl ghrelin concentrations observed in adults following a mixed meal or a glucose load, is already present in obese, anorexic and normal weight adolescents. 27, 28 Nutrition support in anorexic adolescents or weight loss in obese adolescents is associated with a normalization of fasting ghrelin concentrations. 29 Prader-Willi syndrome (PWS) represents an important exception to the association of weight excess with lower plasma concentrations of ghrelin. PWS is a genetic disorder occurring in 1/10 000-1/20 000 live births. Clinical characteristics include neonatal and infantile central hypotonia with poor feeding followed after 1-3 years by excess food intake. Obesity is a cardinal feature of PWS and results mainly from hyperphagia, persistent hunger with increased energy intake, decreased perception of satiety and compulsive behavior that is primarily food related. 30 Interestingly, and in contrast to obese adolescents without PWS, obese children and adolescents with PWS are characterized by elevated ghrelin concentrations, raising the possibility that ghrelin may play a role in the food-seeking behavior observed in these subjects. [31] [32] [33] Daily administration of the short-acting form of octreotide, a somatostatin analog, was shown to cause a significant decrease in ghrelin concentrations in patients with PWS. 31 In a 56-week prospective, randomized, crossover trial, we tested the hypothesis that therapy with the long-acting form of octreotide would cause a prolonged decrease in ghrelin concentrations, food intake and weight gain in patients with PWS. Nine patients with PWS (age 14.6 (1.0) years, BMI Z-score þ 2.0 (0.3), mean (s.e.)) received either octreotide (30 mg) or saline every 4 weeks for 16 weeks and were switched over to the other treatment after a 24-week-washout period. Octreotide caused a marked decrease in both acylated (À55%) and desacyl (À43%) ghrelin concentrations, and was associated with a loss of the physiological postprandial decrease in desacyl ghrelin (Figure 1 ). However, octreotide did not significantly affect weight, body mass index, appetite or compulsive behavior toward food. 34 Although we cannot rule out the possibility that the effect of lower circulating ghrelin is mitigated by an octreotide induced decrease in anorexigenic peptides such as glucagon-like peptide 1 or peptide YY, these data do not support the concept that excess ghrelin causes the hyperphagia characteristic of PWS.
Maternal ghrelin and perinatal growth
In pregnant rats, similar to non-pregnant animals, the stomach is a major source of ghrelin, whereas ghrelin concentrations are low in the pancreas. 8 Before delivery, concentrations of total ghrelin are 2-3 times higher in the fetus than in the dam. Fasting causes an increase in circulating ghrelin in the pregnant rat, but fetal ghrelin concentrations are insensitive to changes in fetal blood glucose caused by maternal fasting and refeeding. 8 Interestingly, exogenous administration of ghrelin during pregnancy or during lactation was shown to affect perinatal growth. Injection of ghrelin to the dam during the last week of gestation caused a 10-20% increase in birth weight, an effect attributed to the transplacental transfer of the injected ghrelin and direct anabolic action in the fetus. 35 Administration of ghrelin to the lactating dam during the first 8 days after delivery increased milk production and caused a 30-40% weight increase in the pups. In humans, we recently observed a modest decrease in total ghrelin concentrations during the second and third trimesters of pregnancy compared with the early postpartum period. Interestingly, these changes were almost exclusively due to a 90% decrease in the concentrations of acylated ghrelin, measured by a new double-antibody sandwich assay specific for the full-length peptide. We also observed a significant positive correlation between the ratio of acylated to total circulating ghrelin in the pregnant mother during the third trimester of gestation and birth weight. 37 Taken together, these data raise the possibility that maternal ghrelin could affect energy balance both pre-(through a direct anabolic effect of ghrelin in the fetus) and postnatally (through increased milk production).
Conclusion
Ghrelin is present in humans and rodents during fetal and postnatal development. The pancreas is an important source of ghrelin in the fetal and early postnatal period, whereas gastric production increases progressively after birth. Although a direct role of endogenous ghrelin on GH secretion during development remains to be clarified, the constitutive activity of GHSR has been shown to contribute to linear growth. The demonstration that loss of function of ghrelin or ghsr genes in mice protects against the obesogenic effects of a high fat diet points toward a role for ghrelin in the maturation of the metabolic systems involved in energy balance. Finally, the observation that the administration of acylated ghrelin to pregnant and lactating dams stimulates fetal and postnatal growth raises the intriguing possibility that maternal ghrelin plays a role in perinatal growth.
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